Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Bio-Rad Introduces New Bio-Plex Pro™ RBM Kidney Toxicity Panels

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
The Bio-Plex Pro™ RBM human, rat, and canine kidney toxicity panels enable early detection and characterization of kidney toxicity and injury during drug development.

Bio-Rad Laboratories, Inc. has announced the launch of its new Bio-Plex Pro RBM human, rat, and canine kidney toxicity panels at the 2013 Society of Toxicology (SOT) annual meeting in San Antonio, TX, March 10-14.

Developed through a partnership with Myriad RBM, Inc., the multiplex immunoassays comprise a set of biomarkers that addresses the need for early detection and characterization of kidney toxicity and injury during drug development.

Acute kidney injury (AKI) is a potentially deadly condition frequently caused by kidney damage due to drug exposure, trauma, or blood loss during a medical procedure.

In contrast, chronic kidney injury (CKI) results from long-term diseases such as diabetes, high blood pressure, or an inherited syndrome.

Protein biomarkers found in urine can signal early signs of kidney toxicity and injury and may provide additional information about the location and severity of damage.

The Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury.

This early detection will allow for more efficient drug testing in both preclinical and clinical research settings.

“The decades-old current clinical tests are not able to detect damage early enough, as evidenced by the fact that two-thirds of the kidney may be irreparably damaged once the traditional biomarkers become elevated,” said Dr. Dominic Eisinger, director of strategic development for Myriad RBM.

Dr. Eisinger continued, “The Bio-Plex Pro RBM panels encompass the most sensitive early markers of kidney injury for preclinical and clinical studies.”

The toxicity panels contain six of the seven markers approved by the FDA and EMEA for use in preclinical kidney toxicity assessment.

Included in these panels are several other markers relevant to kidney toxicity and damage research. The assays are offered as kits that include everything needed to run the assay.

“The Bio-Plex Pro RBM kidney toxicity assays will allow preclinical researchers to monitor biomarker profiles that may predict drug toxicity in the clinic,” said Chris Linnevers, Bio-Rad’s Bio-Plex global product manager.

Linnevers continued, “They also enable clinical researchers to monitor both disease progression and kidney injury during drug trials, which ultimately leads to better-optimized treatment and improved patient care.”

Dr. Eisinger will give a talk on the new assays at the SOT annual meeting. His talk, “Multiplex detection of drug-induced kidney toxicity with new Bio-Plex Pro RBM assays,” will review the need for sensitive and robust assays to evaluate and diagnose kidney injury.

Investigators involved in preclinical and clinical studies of drug safety will learn about the analytical validation of the kits, including their performance in kidney injury studies.

Additional benefits of the Bio-Plex Pro RBM assays include:
• High performance - offer robust quantification of multiple proteins in human, rat, and canine urine samples
• Consistent results - optimized for high precision and lot-to-lot reproducibility of sample measurements
• Simple workflow - formatted on magnetic beads for simplified plate processing and rapid results

The Bio-Plex Pro RBM kidney toxicity panels are compatible with Bio-Plex® MAGPIX™ instruments and Bio-Plex 100/200 and 3D instruments as well as all Luminex platforms and software.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Bio-Rad Announces Web Seminar Series
Web seminar series area includes Spectroscopy, Chromatography, ADME/Tox and Metabolomics.
Friday, May 05, 2006
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Long-Sought Protein Sensor for the ‘Sixth Sense’ Discovered
In a study led by scientists from The Scripps Research Institute (TSRI)the sensor protein for propioception has been identified.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos